Navigation

Personal tools

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit https://cc.nih.gov/.

Updates regarding government operating status and resumption of normal operations can be found at https://USA.gov/.

You are here: Home / Biomarkers / IGF2

IGF2

Basics

Aliases:
This biomarker is also known as:
  • IGF-II,
  • C11orf43,
  • FLJ44734,
  • PP1446,
  • INSIGF,
  • FLJ22066,
  • Insulin-like growth factor II,
  • insulin-like growth factor 2 (somatomedin A),
  • pp9974,
  • chromosome 11 open reading frame 43,
  • Somatomedin-A,

Description…

IGF2 is a member of the insulin family of polypeptide growth factors that is involved in development and growth. The IGF2 gene is an imprinted gene and is expressed only from the paternally inherited allele. It is a candidate gene for eating disorders. There is a read-through, INS-IGF2, which aligns to this gene at the 3' region and to the upstream INS gene at the 5' region. Alternatively spliced transcript variants, encoding either the same or different isoform, have been found for this gene. IGF2 is influenced by placental lactogen and may play a role in fetal development.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: IGF2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

Overexpression of the imprinted insulin-like growth factor-II (IGF2) is a prominent characteristic of gynecologic malignancies. Elevated IGF2 expression is a frequent event in serous ovarian cancer and this occurs in the absence of IGF2 loss of imprinting (LOI).

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. IGF2 alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

No associated publications found.

Biomuta

Mutation Statistics

Gene Name: IGF2
UniProt Accession #: P01344
Mutated Sites Count: 66
Associated Pubmed ID Count 8
CancerDO Count 13
Affected Protein Function Sites Count: 1

View in BioMuta